Gene variants protect against relapse after treatment for hepatitis C

Researchers at the Sahlgrenska Academy, University of Gothenburg, have identified a gene, which explains why certain patients with chronic hepatitis C do not experience relapse after treatment. The discovery may contribute to more effective treatment.

More than 100 million humans around the world are infected with hepatitis C virus. The infection gives rise to chronic , which may result in reduced , and liver cancer. Even though anti-viral medications often efficiently eliminate the virus, the infection recurs in approximately one fifth of the patients.

Prevents incorporation in DNA

Martin Lagging and co-workers at the Sahlgrenska Academy have studied an enzyme called inosine trifosfatas (ITPase), which normally prevents the incorporation of defective building blocks into RNA and DNA.

Unexpectedly they found that the gene encoding for ITPase (ITPA) had significance for the treatment outcome in C virus infection.

Five times lower risk

Earlier studies had shown that approximately one third of all people carry variants of the ITPA gene that result in reduced ITPase activity. The research team at the Sahlgrenska Academy showed that patients with these gene variants exhibited a more than a five times lower risk of experiencing relapse after treatment.

Relapse a significant problem

The study encompassed over 300 patients and was carried out in cooperation with hepatitis researchers in several Nordic countries.

"Relapse after completed treatment is a significant problem in chronic hepatitis C, and the results may contribute to explaining why the infection recurs in many patients. Our hypothesis is that a low ITPase activity results in defective nucleotides being incorporated into the virus RNA, which makes the virus unstable," Martin Lagging said.

Important to other virus infections

According to Martin Lagging, the discovery may also have significance for other .

"A medication that interferes with the enzyme's activity could have a broad antiviral effect, but this must be further investigated in future studies."

More information: Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3, DOI: 10.1002/hep.27009

Related Stories

Recommended for you

UK nurse cured of Ebola after receiving new treatment

date 17 minutes ago

A British army reservist who contracted Ebola while working as a volunteer nurse in Sierra Leone has fully recovered after becoming the first patient in the world to receive an experimental new treatment.

COPD takes big toll on employment, mobility in US

date 44 minutes ago

(HealthDay)—The respiratory illness known as COPD takes a toll on mobility and employment, with a new report finding that nearly one-quarter of Americans with the condition are unable to work.

Genetic test for inherited kidney diseases developed

date 3 hours ago

Many kidney disorders are difficult to diagnose. To address this problem, scientists and clinicians have developed a diagnostic test that identifies genetic changes linked to inherited kidney disorders. This ...

Diagnosing infectious diseases at the point-of-care

date 4 hours ago

A major problem with current testing for infectious diseases in Africa is that it focuses on individual diseases and cannot reliably discriminate between them. Since most infectious diseases have the same ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.